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ABSTRACT
Kidney stone disease involves the aggregation of stone-forming
salts consequent to solute supersaturation in urine. The
development of novel therapeutic agents for this predominantly
metabolic and biochemical disorder have been hampered by the lack
of a practical pre-clinical model amenable to drug screening. Here,
Drosophilamelanogaster, an emergingmodel for kidney stone disease
research, was adapted as a high-throughput functional drug screening
platform independent of the multifactorial nature of mammalian
nephrolithiasis. Through functional screening, the therapeutic
potential of a novel compound commonly known as arbutin that
specifically binds to oxalate, a key component of kidney calculi, was
identified. Through isothermal titration calorimetry, high-performance
liquid chromatography and atomic force microscopy, arbutin was
determined to interact with calcium and oxalate in both free and bound
states, disrupting crystal lattice structure, growth and crystallization.
When used to treat patient urine samples, arbutin significantly
abrogated calculus formation in vivo and outperformed potassium
citrate in low pH urine conditions, owing to its oxalate-centric mode of
action. The discovery of this novel antilithogenic compound via
D. melanogaster, independent of a mammalian model, brings greater
recognition to this platform, for which metabolic features are primary
outcomes, underscoring the power of D. melanogaster as a high-
throughput drug screening platform in similar disorders. This is the first
description of the use of D. melanogaster as the model system for a
high-throughput chemical library screen.
This article has an associated First Person interview with the first
authors of the paper.
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INTRODUCTION
Nephrolithiasis (kidney stones) is a common urological disorder
affecting ∼10% of the population in industrialized nations (López
and Hoppe, 2010; Romero et al., 2010). In the United States, the
prevalence of stone disease has increased from 5.2% (1994) to 8.4%
(2012) (Scales et al., 2012). Globally, the incidence and prevalence
of nephrolithiasis demonstrates a similar trend and contributes
significantly to the development of chronic kidney disease (CKD)
(El-Zoghby et al., 2012; Romero et al., 2010). The economic burden
of nephrolithiasis is substantial, with annual spending reported at
$5.3 billion in the United States alone (Kovshilovskaya et al., 2012).
Despite sizeable nephrolithiasis-related costs and morbidity, with
5-year recurrence rates approaching 50% in affected individuals, a
complete understanding of nephrolithiasis on the molecular level
remains lacking (Katsuma et al., 2002; Lotan et al., 2004). The
pathogenesis of calcium oxalate nephrolithiasis, the most common
stone subtype (80%), is multifactorial (Finkielstein, 2006).
Predisposing factors include metabolic disorders, such as
hypercalcuria, hyperoxaluria or hypocitraturia, and environmental
factors, such as diet. These etiological elements disturb the
metastable biochemical homeostasis of urine, ultimately
culminating in crystal deposition and stone formation (Pak, 1998).
Medical treatment prevention strategies for calcium oxalate
nephrolithiasis, which have remained relatively stagnant since the
mid-1980s, vary based on underlying etiology. Current evidence
suggests that potassium citrate and thiazide diuretics are effective
agents in the prevention of calcium oxalate stone formation in
hypocitraturia and hypercalcuria states (Qaseem et al., 2014; Reilly
et al., 2010). In contrast, in primary and idiopathic hyperoxaluria,
proportionately important sources of calcium oxalate stone
formation, evidence is sparse for a consistently effective medical
treatment. Pyridoxine has been suggested in the past based on
several small nonrandomized clinical trials (Balcke et al., 1983;
Mitwalli et al., 1988; Rattan et al., 1994). Newer approaches, such as
probiotic and oxalate decarboxylase treatment, have generated
mixed results (Moe et al., 2011; Xu et al., 2013).
Progress has perhaps been limited owing to a lack of suitable pre-
clinical models that reliably recapitulate the pathophysiology of this
disorder. Several animal models have previously been established
for the study of nephrolithiasis, including rat, mouse, porcine and
canine models (Khan, 1997). Historically, the most prominent
among these has been the rat model of nephrolithiasis. The rat modelReceived 31 May 2018; Accepted 25 July 2018
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relies on dietary manipulation or intraperitoneal injection of
lithogenic agents (ethylene glycol, ammonium chloride or vitamin
D3) to induce calculus formation (Khan, 1997; Liu et al., 2007). The
use of this model has generated variable results with inconsistent
stone formation. In addition, the nephrotoxicity of the lithogenic
agents has limited overall model utility (Khan and Glenton, 2010;
Khan et al., 2006).
Drosophila melanogaster has recently emerged as a promising
model of human nephrolithiasis (Miller et al., 2013). A rapid
reproductive rate and a fully mapped and mostly understood
genome, in tandem with experimental simplicity, make D.
melanogaster a particularly powerful model. The renal system of
D. melanogaster consists of two discrete components: nephrocytes
and Malpighian tubules (MTs). As a unit these components display
a remarkable degree of similarity in form and function to the human
nephron. Nephrocytes form a collection of cells around the heart and
esophagus that filter waste products from hemolymph in a fashion
analogous to the human glomerulus, generating urine by active
transport of water, ions and solutes into the MT lumen (Hirata et al.,
2012; Miller et al., 2013; Weavers et al., 2009). Recent work using
D. melanogaster has successfully produced calcium oxalate-based
stones present within the MTs of D. melanogaster, and identified
the role of oxalate co-transporters (SLC26A6) and the role of excess
zinc in stone formation (Chi et al., 2015). Contents of the MTs are
subsequently moved via peristalsis into the hindgut, where they are
mixed with the fecal matter being produced in that organ. We
discovered that the stones formed in the MTs are also present within
fecal matter and could provide a noninvasive way of determining
stone formation in vivo (Cognigni et al., 2011).
With this discovery, we developed novel imaging techniques for
visualizing and quantifying calcium oxalate stone burden in the
Drosophilamodel of calcium oxalate nephrolithiasis. This led to the
development of a functional high-throughput screening platform,
allowing us to screen chemical libraries to identify novel
compounds that exhibit antilithogenic activity in vivo and are
ingestible. Although this model does not fully recapitulate
mammalian calculi formation processes, we successfully
identified compounds that were highly effective at halting
calculus formation. Hydroquinone β-D-glucopyranoside,
commonly known as arbutin, is a glycoside with hydroxyquinone
(HQ) moieties, most commonly isolated from the Arctostaphylos
uva-ursi or Bearberry dwarf shrub (Pop et al., 2009). Arbutin was
seen to bind both free calcium ions as well as oxalate, serving as a
dual antagonist to calcium oxalate crystallization. This discovery
indicated that other novel antilithogenic compounds can be
discovered in a similar manner, owing to the primarily acellular
development of kidney stones.
RESULTS
Bisphosphonate probes bind to calcium oxalate calculi
formed by Drosophila
We previously demonstrated that alendronate-fluorescein
isothiocyanate (FITC), a fluorescently labeled bisphosphonate,
binds to oxalate calculi via petrographic thin sections of calcium
oxalate kidney stones and to nanocrystals in patient urine samples
(Gavin et al., 2016). Pulverized calcium oxalate kidney stones were
stained with alendronate-FITC and hydroxyapatite nanoparticles
were used as a positive control, revealing a high binding affinity of
the alendronate-FITC bisphosphonate probe to calcium oxalate
calculi (Fig. 1A; Fig. S1A). Calcium oxalate calculi were formed in
Drosophila by supplementing standard fly medium with varying
amounts of sodium oxalate (0, 0.01, 0.05, 0.1, 0.5, 1.0% w/w) or
ethylene glycol (0.1, 1, 2, 5% v/w). However, sodium oxalate
produced the most consistent calculi formation in the MTs of
D. melanogaster compared with polyethylene glycol (∼99% vs
93%, respectively). Newly eclosed Drosophila were added to fly
tubes containing supplemented fly medium and incubated for 5-
14 days (Fig. 1B). The GAL4-UAS system (Duffy, 2002), a potent
tool for modifying gene expression, was utilized to develop
transgenic fly lines to enhance imaging. Larvae were imaged for
the presence of calculi within their MTs using Drosophila that
express the fluorescent protein RFP in the MTs (UAS-RFP×URO-
GAL4 cross) (Fig. 1C, top; Fig. S1B), with birefringence signal
representing calculi within theMTs (Fig. 1C, bottom). MTs positive
for birefringence signal were dissected and stained with
alendronate-FITC, suggesting that formed calculi are calcium
oxalate based (Fig. 1D; Fig. S2). Dissected MTs (Fig. 1E) and
their resident calculi were submitted to energy-dispersive X-ray
(EDX) spectroscopy, revealing the elemental composition of calculi
to be calcium oxalate monohydrate (Fig. 1F) and dihydrate
(Fig. 1G). This EDX spectroscopy analysis suggests that
Drosophila produce calcium oxalate calculi in vivo that are
elementally similar to those found in humans.
D. melanogaster birefringence-positive fecal excreta as a
high-throughput screening method for antilithogenic agents
Oxalate-based calculi are found throughout the MTs in addition
to the fly hindgut. Increased concentrations of sodium oxalate
added to standard fly medium resulted in a proportional increase in
stone burden within MTs. Birefringence signal (crystals) and
alendronate-FITC staining (calcium oxalate) were utilized to
quantitate stone/crystal burden (Fig. 2A). Increasing sodium
oxalate concentration did, however, impact fly survival over
time (Fig. 2B); therefore, a 0.5% w/v concentration of sodium
oxalate was used in all subsequent experiments. A fecal excreta
assay was developed to quantify changes in stone burden by
inserting a coverslip in the sponge lid of fly tubes during
incubation. D. melanogaster responded by passively depositing
calculi-rich fecal excreta onto the coverslip (Fig. 2C, left and
middle), which was then subjected to polarized light microscopy
for birefringence signal representing crystals/calculi. Examination
of a single fecal droplet revealed autofluorescence with highly
birefringent mineral-like bodies within the fecal deposit. No such
birefringent signal was observed in fecal deposits with a standard
diet (Fig. 2C, right).
A drug library screen (Lee et al., 2015; Rota et al., 2017;
Spagnuolo et al., 2010) was performed, in which each drug was
mixed into fly medium supplemented with 0.5% sodium oxalate to a
final concentration of 20 µM drug (Fig. 3A). After 7 days of
incubation and ingestion of drug candidates, the viability of flies
was quantitated and all coverslips containing fecal excreta were
analyzed for birefringence signal (Fig. 3B). Assessment of all
coverslips was based on an arbitrary scale of 10 to 1 in terms of both
fecal excreta (visual inspection of the entire coverslip) and calculi
(via confocal microscopy of birefringence signal). Dimethyl
sulfoxide (DMSO) controls were all 10 with regards to fecal
excreta score and calculi score. A ‘hit’ was considered to be 10-5 in
terms of fecal excreta scoring and 1 in terms of calculi score. Drug
library screening (Fig. 3C, n=360 compounds), which included
various negative and positive controls, yielded a minority of drug
‘hits’ that were toxic (1-5 in terms of fecal excreta score) and had no
impact on calculi formation (n=28, 7.8%). The majority of
candidate drugs did not impact D. melanogaster viability (5-10 in
terms of fecal excreta score). Drug screening yielded a small number
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of drugs that decreased calculi score (1-5 in terms of calculi score)
with minimal impact on D. melanogaster viability (5-10 in terms of
fecal excreta score) (n=28; Fig. 3C, red gate, 7.8% of all drug
candidates tested). Of these, eight were found to exhibit the greatest
decrease in calculi formation (Fig. 3C, green gate). A second
focused drug screen (n=8) was performed to confirm the
antilithogenic effect in vivo; this second tier of analysis yielded
two compound ‘hits’ that consistently exhibited antilithogenic
activity in vivo; arbutin and cucurbitacin β-2-O-glucoside (Fig. 3E).
Of these, arbutin was chosen as a proof of principle to validate the
potential of D. melanogaster as a high-throughput model for drug
screening.
Fig. 1. Calcium oxalate calculi formation in D. melanogaster. (A) Confocal and birefringence images of pulverized human calcium oxalate crystals (upper row)
and synthetic hydroxyapatite particles (lower row) stained with alendronate-FITC probe. Scale bars: 1 mm. (B) Schematic of D. melanogaster model of
calcium oxalate calculi formation within Malpighian tubules (MTs). (C) Intravital imaging of birefringence signal representing oxalate-based calculi within MTs of
D.melanogaster larvae. Intravital imaging of RFP-expressing diet-induced calcium-oxalate-stone-carryingD.melanogaster larvae. Arrow indicates anRFP+MTwith
birefringent signal (C, bottom). Scale bars: 1 mm. (D) Dissected MTs reveal the presence of alendronate-FITC-positive deposits (arrows) within RFP+ MTs,
confirming the presence of oxalate-based calculi. Scale bars: 25 µm. (E) Dissected MTs as imaged by brightfield or scanning electron microscopy (SEM). Dashed
arrow represents fly Malpighian tubule and gut complex. Solid arrow shows an MT calculus. (F) SEM/energy-dispersive X-ray (EDX) analysis of calcium oxalate
monohydrate calculi extracted from MTs. Scale bar: 3 µm. (G) SEM/EDX analysis of calcium oxalate dehydrate calculi extracted from MTs. Scale bar: 3 µm.
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Arbutin is an effective antilithogenic agent
Arbutin is a glycoside with a hydroxyquinone side chain with no
previous reports regarding interactions with oxalate or calcium.
When supplemented to fly medium+0.05% sodium oxalate, arbutin
at 1 mM resulted in a near abrogration of calculi deposits in
dissected MTs when compared with controls (fly medium+0.5%
oxalate±DMSO) (Fig. 4A,B). Calculi content deposited in fecal
excreta significantly decreased at >64 µM arbutin (Fig. 4C) with a
calculated half-maximal inhibitory concentration (IC50) of 40 µM.
Observed decreases in calculi content in fecal excreta corresponded
with decreases in calculi content in MTs (Fig. 4D, 32 µM and
512 µM arbutin treatment).
In addition, urine samples from human patients with recurrent
calcium oxalate kidney stones were added to fly medium with no
sodium oxalate supplementation (Fig. 4E). Drosophila incubated in
this manner generated calculi in the same manner as those incubated
with fly food supplemented with sodium oxalate. This patient-
urine-based model (n=10 patients) was used to compare the
antilithogenic effect of arbutin compared with that of potassium
citrate, an established therapy for oxalate-based kidney stone
patients. Using 1 mM final concentrations in fly medium, arbutin
administration led to a significant decrease in stone burden via fecal
excreta assay in comparison with citrate, regardless of pH. Various
pHs were evaluated in order to recapitulate the pH of human urine in
the kidney and bladder (pH 4-6), with a greater reduction in calculi
formation observed at pH 7-8.
Arbutin binds to both free calcium ions and oxalate
Arbutin was incubated with calcium chloride and then submitted
to scanning electron microscopy (SEM), revealing clusters of
arbutin and calcium (Fig. 5A, top) in a 1:4 stoichiometry, as
determined by EDX spectroscopy (Fig. 5A, bottom). Isothermal
calorimetry was used to determine whether a specific chemical
interaction occurs between two agents of interest, with the release
of heat indicative of chemical bonding (exothermic). Titration of
either arbutin or calcium chloride to the other component revealed
an exothermic reaction that plateaued at a molar ratio of 4.03
(Fig. 5B). High-performance liquid chromatography (HPLC) and
mass spectrometry of arbutin and calcium chloride mixtures
revealed peaks representing free arbutin, arbutin complexed with
calcium ion, and arbutin complexed with calcium ion and water
(Fig. 5C). HPLC and mass spectrometry of arbutin and sodium
oxalate also revealed peaks representing arbutin+oxalate+water
and arbutin+oxalate.
Fig. 2. Calculi present in fecal excreta of Drosophila as a drug discovery platform. (A) Increasing amounts of sodium oxalate in fly medium induced
kidney stone formation, present within MTs as evidenced by birefringence signal and alendronate-FITC signal. (B) D. melanogaster survival on sodium oxalate-
treated fly medium over a 60-day period. (C) D. melanogaster deposit calculi-rich fecal excreta on the fly tube wall (green, autofluorescence of fecal matter)
and coverslip attached to sponge lid. Flies grown in sodium oxalate-rich fly medium produce fecal excrement-containing birefringent bodies representing calculi
(white, birefringence signal).
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Arbutin binds to the surface of oxalate-based nanocrystals
Large sodium oxalate crystals were formed for confocal
birefringence microscopy to determine whether arbutin binds
directly to the surface of calculi. Sodium oxalate calculi imaged
in this manner revealed polygonal and smooth surfaces on oxalate-
based crystals (Fig. 6A, left). Incubation with arbutin resulted in
crystal surface aberrations (Fig. 6A, right). To confirm that arbutin
binds to the surface of oxalate-based crystals, atomic force
microscopy (AFM) was performed on both crystal types, with
oxalate-only crystals revealing a smooth and uninterrupted surface
according to scan line roughness analysis (Fig. 6B). Oxalate crystals
treated with arbutin revealed a highly active crystal topography
(Fig. 6C, red arrows), with a roughness index higher than in the
untreated crystal. Oxalate-based crystals were also significantly
smaller than nontreated crystals, based on AFM volumetric analysis
(Fig. 6B,C).
Arbutin inhibits oxalate-based toxicity in vitro
Human embryonic kidney epithelial (HEK) cells grown in vitro
incubated in 20 μM sodium oxalate were associated with
significantly lower cell viability rates than those grown in control
conditions, with some nanocrystals observed within cells over the
incubation period (Fig. 7A). However, addition of arbutin (1 mM
final) into the medium ameliorated this effect, with no impact on
cell viability or lactate dehydrogenase (LDH) activity compared
with arbutin treatment alone (Fig. 7B,C). No birefringent signal was
observed within these cells.
DISCUSSION
Aside from the divalent ions, calcium and magnesium, there are
currently no known sequestrants for free and bound oxalate,
the principal component of calcium oxalate calculi. Despite
the limitations of D. melanogaster as a pre-clinical model of
Fig. 3. Drug screening results using fecal excreta and calculi present within fecal excreta from D. melanogaster colonies. (A) Schematic of in vivo
drug library screens for antilithogenic compounds based on the calculi-fecal excreta coverslip assay. (B) Representative images of calculi or excreta density
based on an arbitrary scale from 10 (highest/most dense) to 1 (lowest). A DMSO vehicle control with a score of 10 for calculi is shown. A representative ‘hit’ with a
score of 1 for calculi is shown. Scale bars: 4 mm. (C) Drug screening results from a chemical library representing 360 naturally occurring compounds. ‘Hits’
were defined as coverslips that yielded a ‘1’ score for calculi deposition with no toxic impact onD.melanogaster viability (5-10 in terms of fecal excreta score, green
gate). (D,E) A second focused library screen with the eight hits (D) yielded a final list of two active compounds (E). After tertiary analysis of the two active
compounds, one was validated, arbutin.
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nephrolithiasis, we hypothesized that it could have some value as a
high-throughput screening platform for identifying small molecules
that inhibited calcium oxalate calculus formation in vivo, owing to
the predominantly acellular metabolic and biochemical nature of
nephrolithiasis. To our knowledge, this is the first high-throughput
chemical library screen using D. melanogaster. This screening
platform relies on the dietary administration of candidate drugs to
observe changes in calculus composition via the described fecal
excreta assay. This innovation permitted an unbiased ‘drop out’
screen to be performed for each candidate drug when ingested.
Another key innovation was the use of a natural compound library
that focused the screen to compounds that would not elicit a
nephrotoxic effect, which is a current drawback of standard
therapies of calculi. Screening a library of 360 different small
Fig. 4. Arbutin and its antilithogenic effects on oxalate-based calculi. (A) Polarized microscopy of MTs treated with arbutin compared with standard
medium and oxalate-supplemented fly medium. (B) Percentage of fecal excreta area that contains birefringence signal/calculi when flies are grown in various fly
medium treatments, including arbutin. *P<0.01 with two-way ANOVA, Scheffe α correction. (C) Dose-dependent inhibition of oxalate-based fecal excreta
deposited byDrosophilawith various concentrations of arbutin. (D) Microscopy of coverslips deposited with calculi-rich fecal excreta and dissected MTs when fly
medium is supplemented with 0, 32 and 512 µM arbutin. (E) Schematic of patient urine-based kidney stone in vivo formation assay. Patient urine samples are
added to fly media with and no other supplementation. Coverslips containing calculi-rich fecal excreta are analyzed via microscopy. Vehicle image for
coverslip analysis is DMSO sample reproduced from Fig. 3B; drug image is from the image labeled 2 in Fig. 3B. (F) The patient urine-based kidney stone in vivo
formation assay was used to compare potassium citrate with arbutin at various pHs. Coverslips containing calculi-containing fecal excreta were analyzed by
birefringence microscopy. *P<0.05, two-way ANOVA, Scheffe α correction.
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molecules led to the identification of two compounds of
antilithogenic activity, with arbutin producing the greatest effect.
These antilithogenic effects were in magnitude to those observed
with citrate treatment, further supporting the candidate ‘hits’.
The percentage of candidate hits that resulted in significant
toxicity and decrease in D. melanogaster viability with the chosen
screening dose was unexpected. This meant that ≥7.8% of screened
compounds should have been evaluated at a log-fold lower dose,
meaning that a proportion of these could have been drug candidates
that otherwise were as effective as arbutin but at a lower dose. Re-
screening these was not performed. This is a flaw in the study design
because it would have prompted more screens of the library with no
true termination point. The dose used was similar to other screening
doses and yielded an acceptable viability rate of 92%. Upon
completion of the first pass of the library screen, the set of candidate
drugs discovered led to focused studies on a single compound.
Discovery of an antilithogenic compound validated the capability of
the screen, which was the main goal of the study.
Arbutin is currently used as a nonpharmaceutical herbal
supplement in the form of a plant-based extract [Bearberry Leaf
Dry Extract (BDLE)] for the prevention of urinary tract infections
(Schindler et al., 2002). It is also an active ingredient in skin
lightening creams, although a risk-benefit approach has been
advised with use in this role owing to a skin sensitization effect
(O’Donoghue, 2006). It is also present in significant quantities in
wheat-based products, pears, coffee and tea. Interestingly, recent
studies have associated the regular consumption of coffee and
certain teas with a lower risk of stone formation (Ferraro et al., 2014;
Stamatelou et al., 2003). A higher urinary excretion rate of calcium,
decreased calcium oxalate supersaturation and decreased urinary
oxalate was seen in caffeinated coffee drinkers (Ferraro et al., 2013,
2014).
The pharmacokinetic profile of arbutin is partially established; it
is reported to be heavily absorbed from the gastrointestinal tract and
is bioavailable as HQ by-products [Chemical Information Review
Document for Arbutin (CAS No. 497-76-7) and Extracts from
Arctostaphylos uva-ursi; https://ntp.niehs.nih.gov/ntp/htdocs/
chem_background/exsumpdf/arbutin_508.pdf ]. In previous
human studies, 4 h after an oral dose of arbutin, ∼70% of the
administered arbutin dose was retrieved in the urine as HQ
conjugates, demonstrating renal excretion (Glöckl et al., 2001).
The remainder could potentially be accounted for as free arbutin,
available to interact with formed calcium oxalate and free
subcomponents in the urine. No data on the plasma and urine
bioavailability of free arbutin are presently available, possibly due to
detection limitations of HPLC-based assays utilized in prior studies.
Fig. 5. Arbutin and its interactions
with calcium and oxalate. (A) SEM
image of arbutin complexed with
calcium. EDX spectra reveal four
calcium ions for every molecule
of oxalate. (B) Isothermal titration
calorimetric analysis of arbutin and
calcium chloride, revealing a molar ratio
of four calcium ions for each arbutin
molecule. (C) Matrix-assisted laser
desorption/ionization (MALDI) spectrum
of calcium and arbutin complexes
formed in solution. (D) MALDI spectrum
of arbutin and oxalate complexes
formed in solution.
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Arbutin has been described to readily degrade into the split
components D-glucose and HQ (and conjugates) in acidic
environments by Deisinger et al. (1996). An enteric coated tablet
vehicle could thus potentially be utilized to bypass hydrolysis by
stomach acids and improve oral bioavailability. However, our
preliminary nuclear magnetic resonance spectroscopy (NMR)
studies of arbutin in acidic conditions suggest that arbutin is
stable and able to bind to oxalate whilst in solution, despite the low
pH (data not shown). From available toxicology data, arbutin has
been shown to have a low risk of acute and chronic toxicity by oral
dosing in rat- and mouse-based experiments with no remarkable
effects observed. Although no genotoxic effects were reported in
in vitro or in vivo studies (Scientific Committee on Consumer
Products: Opinion on β-Arbutin; https://ec.europa.eu/health/ph_
risk/committees/04_sccp/docs/sccp_o_134.pdf), further studies are
needed to complete the toxicological and pharmacokinetic profile of
arbutin and HQ.
The mechanism of arbutin’s antilithogenic action was
evaluated in vitro on calcium oxalate crystals, calculi formed by
D. melanogaster, and calculi induced inD. melanogaster by dietary
supplementation of patient urine content. The mechanism of action
appears to be twofold: arbutin binds to four calcium ions and it can
bind to oxalate in a 1:1 stoichiometric relationship. The ability of
arbutin to interact directly with oxalate is novel; only divalent ions
such as calcium have previously been shown to interact with
oxalate. Experiments with fly medium supplemented with sodium
oxalate (0.5%) revealed antilithogenic abilities at concentrations as
low as 64 µM, suggesting that it directly binds to oxalate, as
confirmed by mass spectrometry. Arbutin also binds directly to pre-
formed oxalate-based calculi, as determined by AFM and mass
Fig. 6. Calcium oxalate and arbutin
crystal structure interaction
analysis. (A) Confocal birefringence
images of pure oxalate crystals prior to
arbutin exposure (left), and following
exposure to arbutin (right). Scale bars:
10 µm. (B) Atomic force microscopy
(AFM) image of pure oxalate crystals.
Insets in the middle panel provide
higher magnification views of the
crystal surface. Scan line analysis of
the height channel within the inset
reveals a smooth topography.
(C) Oxalate crystals exposed to
arbutin reveal a highly active surface
topography decorated with arbutin
drug molecules (red arrows). Insets
in the left panel reveal a rough surface
topography, as shown by scan line
analysis of the height channel.
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spectrometry, disrupting crystal lattice structure. Therefore, it
appears that arbutin’s antilithogenic activity is due to its binding
to key components of calculi: divalent ions (calcium and
magnesium) and oxalate. Translationally, the mode of action of
arbutin could be binding to soluble oxalate in the gastrointestinal
tract or in the blood. It is possible that arbutin’s antilithogenic effect
could be via reduction of dietary oxalate and, in the presence of a
pre-formed stone, complex formation on the stone surface to inhibit
further crystallization.
The observed effects of arbutin in these experiments raise
intriguing questions about the potential for this agent to be used as a
strategy to prevent and/or treat pre-existing human calcium oxalate
stone disease. In patients at risk for calcium oxalate stone formation,
arbutin could, through competitive inhibition, prevent calcium
oxalate binding.
The fecal excreta calculi assay performed via theD. melanogaster
model of human nephrolithiasis is a highly promising in vivo
screening platform for the identification of antilithogenic
compounds. It is flexible and scalable to screening of thousands
of candidate compounds at minimal cost. The use of birefringent
signals to quantitate stone burden via fecal excreta deposited onto
coverslips is an innovation that is cost effective and does not require
any additional processing or staining. It also entails that other
birefringent calculi, such as uric acid calculi, are also amenable to
this type of chemical library screen. This screening platform
provides several avenues of opportunity to narrow down large
numbers of potentially overlooked candidate compounds with
possible clinical applications for further evaluation.
MATERIALS AND METHODS
Drosophila stocks
All fly stocks were reared on standard medium consisting of agar, yeast, milk
powder, corn meal and corn syrup, at 25°Cwith a 12-12 h light-dark cycle at
∼40% humidity. Wild-type Canton S [Bloomington #1, Bloomington
Fig. 7. Cytotoxicity of arbutin and oxalate on human kidney epithelial cells. (A) Confocal fluorescence images of HEK293 cells stained with CellTracker
Red to label the cell surface and Hoechst to label the nuclei. HEK293 cells were treated with 20 µM sodium oxalate for 30 min. Birefringence signal was
observed within HEK293 cells (white signal). Scale bars: 25 µm. (B) Activity of LDH released from HEK293 cells after 30 min incubation with oxalate in the
presence or absence of arbutin. (C) Cell viability in arbutin-treated HEK293 and PC3MLN4 cells over a 3-day period. Green line represents control normalized
to 100% at that same timepoint. ***P<0.05, two-way ANOVA, Scheffe α correction.
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Drosophila Stock Center (BDSC)] fly line was used for all experiments. For
fluorescent tubule imaging, the responder lines UAS-RFP (Bloomington
#32218, BDSC) driven by the GAL4 lines c42 (provided by J. Dow,
University of Glasgow, Glasgow, UK) and URO-GAL4 (Bloomington
#44416, BDSC) were utilized.
Stone and urine sample collection
All experiments and sample collection procedures were approved by local
hospital/institution research ethics board (REB) panels, and assigned as
REB #105604. Patient-derived stone and urine samples were collected from
consenting patients who underwent percutaneous nephrolithotomy.
Approximately 10 ml of the urine was collected via cystoscopy and
subsequently stored at −80°C. Stone samples were collected using either
duckbill forceps or an endoscopic grasping basket and deposited directly
into a sterile container and stored at −20°C. Patient data, stone and urine
analysis data, including oxalate crystal data, were previously presented in an
independent report (Gavin et al., 2016).
Synthesis of alendronate-FITC and its negative isotype control
notdronate-FITC
Bisphosphonates are well known to bind tightly to the surface of bone.
Several groups have conjugated bisphosphates to a fluorophore, which has
been used to image the localization of these bisphosphate groups to bone
(Gavin et al., 2016; Cole et al., 2014). Our imaging agent consists of the
commercially available bisphosphonate drug alendronate conjugated to the
fluorescent dye FITC. As a negative control, the bisphosphonate group of
alendronate was removed, leaving 4-amino-1-butanol conjugated to the dye.
The amine [alendronate or 4-amino-1-butanol (Alfa Aesar)] was dissolved
in saturated NaHCO3(aq). The NHS-ester of fluorescein (Thermo Fisher
Scientific) was dissolved in dimethylformamide (Fisher BioReagents) and
added to the amine. The reaction was stirred in the dark overnight. The
solution was purified by reverse-phase flash column chromatography
(Biotage Isolera One, 12 g C18 SNAP, methanol in water 0-100%) and the
product-containing fractions were lyophilized. The lyophilized powder was
dissolved in water (Milli-Q, 18.2 MΩ cm), dialyzed with water overnight
(Float-A-Lyzer G2, Spectrum Labs), and lyophilized to yield the fluorescent
dye conjugates. All reagents were provided in powder form and stored in a
−20°C freezer in an opaque container.
Testing specificity of fluorescent probes to hydroxyapatite and
calcium-based stones
Synthetic hydroxyapatite particles (Sigma-Aldrich) and pulverized samples of
infrared spectroscopy-confirmed human calcium oxalate stones were stained.
Then, 100 mg of sample was incubated in an Eppendorf tube with 200 ml
0.1 mM alendronate-FITC, 0.1 mM notdronate-FITC and PBS as a control.
Afterwards, the samples were centrifuged (Eppendorf) at 14,000 g for 5 min,
the supernatant was removed and three subsequent washes were performed
with distilled water to remove any unbound dye. The samples were then
mounted onto glass slides with coverslips for confocal microscopy.
Diet-induced calcium oxalate stone formation
Stone-forming diets were prepared using the lithogenic agents sodium
oxalate (Sigma-Aldrich) and ethylene glycol (Sigma-Aldrich). These
compounds were added to the water during the preparation of fly food
medium. Four concentrations were prepared for each lithogenic agent at
0.05%, 0.1%, 0.5% and 1% w/v ratio and stored at 4°C until required.
Twenty newly eclosed flies were added to 15 narrow vials containing
either of the lithogenic diets or standard food medium as a control. The
flies were fed for 7-14 days, after which they were removed for staining
and imaging.
Generation of fluorescent MTs
Fluorescent MTswere generating by crossing fly lines expressing UAS-RFP
with the driver lines c42 and URO-GAL4. URO-GAL4 drives expression in
the principal cells of the MTs and line c724 in the stellate cells. Age-
matched newly eclosed virgin females carrying UAS-RFP were crossed
with newly eclosed males from the driver lines. After 2-3 days of mating and
the laying of eggs, the flies were discarded and the transgenic variants
allowed to mature. After maturation, these flies were reared on either the
lithogenic diets or the standard control diet for 14 days. They were
subsequently dissected and processed for imaging.
Ex vivo staining and imaging of Drosophila MTs
Flies were euthanized by carbon dioxide narcotization using the Flow
Buddy CO2 System (Flystuff ). The MTs were carefully dissected under a
stereomicroscope in a Sylgard (Dow Corning)-lined Petri dish using
Schneider’s media (Sigma-Aldrich). The tubules were mounted on a fresh
Petri dish and minutien pins (Fine Science Tools) were used to anchor the
ends. Each tubule was incubated in either 200 ml 0.1 mM alendronate-
FITC, 0.1 mM notdronate-FITC or PBS for 30 min. Consequently, tubules
were washed several times with PBS and then mounted for wide-field
fluorescence imaging (Nikon), birefringence microscopy (Nikon), or
resonance confocal microscopy (Nikon).
For the MTs expressing RFP, they were first stained with 4′,6-diamidino-
2-phenylindole (DAPI) followed by our fluorescent probes alendronate-
FITC and notdronate-FITC. The tubules were first imaged with normal light
followed by polarized birefringent microscopy and finally imaged with a
scanning laser with a confocal microscope. We used a Nikon TE2000
Inverted Microscope and a Nikon Confocal Microscope for imaging.
X-ray diffraction spectroscopy
Approximately 150 flies fed lithogenic medium were dissected, their MTs
extracted and stored in 1 ml PBS in an Eppendorf tube. Collected MTs were
sonicated for 30 min in a solution consisting of proteinase K and 0.1%
Triton X followed by centrifugation at 14,000 g for 10 min. The supernatant
was discarded. The solids were washed thoroughly with double distilled
water and re-centrifuged. Then, 2 µl sample was mounted on silica wafer for
SEM and X-ray diffraction spectroscopy analysis.
Lifespan study
Drosophila eggs were collected on grape juice agar plates in egg collection
cages (Diamed Inc.). The eggs were washed multiple times with PBS and
32 ml egg solution was pipetted and deposited in vials containing standard
medium. After 10 days, newly eclosed flies were anesthetized using
carbon dioxide and separated by sex. Twenty flies of the same gender were
added to ten vials containing varying concentrations of lithogenic agent or
standard medium as a control. Flies were transferred to vials containing
fresh food on alternate days and the number of deaths recorded. This was
performed over a period of 60 days. Data were analyzed using the
Statistical Package for Social Sciences for Mac (SPSS Version 21 Mac)
and graphical data generated using Graph Pad Prism Software (GraphPad
Prism 6).
Quantification of calcium oxalate calculi via D. melanogaster
excreta birefringence assay
Twenty newly eclosed flies were housed in 15-ml narrow fly vials with
stone-forming medium containing 0.5% (w/v) sodium oxalate. A glass
coverslip (18×18 mm) was suspended from the cotton tube plug to allow
for the collection of fecal matter. Following a 14-day incubation period,
the coverslip was extracted from each tube and each coverslip was directly
imaged by confocal microscopy under polarized light. Control
experiments were performed in a similar fashion with standard medium.
The percentage area of birefringence for each coverslip was individually
analyzed and quantified using NIH ImageJ software (Particle Analysis
function).
Drug library screening
Stone-forming medium containing 0.5% (w/v) sodium oxalate was
prepared. Candidate compounds from our drug library (Lee et al., 2015;
Rota et al., 2017; Spagnuolo et al., 2010) were added to 10 ml of the medium
up to a total concentration of 20 µM drug. This drug library consisted of 360
different compounds diluted to 1 mM in DMSO and stored at −80°C.
Vehicle controls such as PBS and DMSO were used and randomly inserted
into the library. Five milliliters of the total 10 ml mediumwere decanted into
two separate 15 ml narrow vials to perform further experiments as
duplicates. Twenty newly eclosed flies were added to each vial. Following
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a 14-day incubation period, each coverslip was removed and mounted onto
glass sides in preparation for imaging. Each slide was directly subjected to
confocal microscopy under polarized light. The percentage area of
birefringence was quantified and compared with birefringence data from
control experiments with separately prepared 0.5% sodium oxalate media
with no addition of candidate drugs.
Dose-response relationship of hydroquinone arbutin and calcium
oxalate stone formation
Thirty milliliters of 0.5% (w/v) sodium oxalate medium was prepared with
19.3 mM arbutin. A tenfold serial dilution was performed to obtain 15 ml
medium per dilution. Each dilution was divided into three narrow fly vials to
yield triplicates. Twenty newly eclosed flies were added to each vial with a
glass coverslip (18×18 mm) suspended from the cotton vial plug to collect
fecal matter. After a 14-day incubation period, each coverslip was extracted
and stone burden was quantified as previously described to observe the
dose-response relationship between arbutin concentration and percentage
area of birefringence.
Patient-derived urine-based calcium oxalate stone induction
in D. melanogaster
Urine samples were collected from recurrent calcium oxalate stone-forming
patients and centrifuged at 1000 g. One-milliliter aliquots of supernatant
were prepared and stored at −80°C for further analysis. Ten milliliters of
standard medium were prepared and thoroughly mixed with 1 ml patient
urine; this was separated into two individual narrow vials (5 ml per vial).
Twenty newly eclosed flies were added to each vial. A glass coverslip
(18×18 mm) was suspended from the cotton vial plug to collect fecal matter.
This experiment was repeated with patient urine-containing diet in the
presence of 3 mM arbutin. Following a 14-day incubation period, each
coverslip was extracted and imaged as described previously. Stone burden
on each coverslip was quantified via the aforementioned birefringence assay
and results were expressed as mean±s.e.m. Percentage stone burden was
analyzed using one-way analysis of variance (ANOVA) (Prism 6, GraphPad
Software, San Diego, CA, USA).
In vitro patient-urine based analysis of arbutin and calcium
oxalate interactions
Fifty microliters of patient urine were combined with 45 µl 20 mM HEPES
buffer (pH 7-8). Five microliters of 20 mM arbutin were added to each
solution to form a 1 mM final concentration of the drug. Immediately after
addition of the drug, 5 µl of each sample was spotted on a glass slide and
birefringence data were imaged on confocal microscope. Each sample was
incubated at 37°C for 24 h. Five microliters of the sample were identically
collected and reimaged. Data on percentage area of birefringence were
analyzed as previously described. This experiment was repeated in sodium
acetate/acetic acid buffer at a pH of 4 to observe the efficacy of arbutin in
acidic environments. Reduction of percentage stone reduction was analyzed
using one-way ANOVA. Control experiments were conducted using Quick
Fix Plus synthetic urine from Spectrum Labs, Cincinnati, OH, USA.
Isothermal calorimetric titration of arbutin and calcium chloride
To investigate the interaction between arbutin and calcium ions, 75 mM
calcium chloride and 1 mM arbutin solutions were prepared in 20 mM
HEPES buffer at pH 7.4 in preparation for isothermal titration calorimetry.
The isothermal calorimetric titration (ITC) binding experiments were
performed in the Nano ITC Standard Volume with a fixed gold cell by
titrating 250 µl injections of 75 mM calcium chloride solution into 1 mM
arbutin solution at 350 s intervals for 1800 s (30 min) with a stirring speed
of 300 rpm. The user-adjustable auto equilibrate function was used to ensure
a stable baseline prior to injection of titrant. ITC data were analyzed with
NanoAnalyze Software (TA Instruments).
Matrix-assisted laser desorption/ionization (MALDI) of arbutin-
calcium and chloride arbutin-sodium oxalate reaction mixtures
To further investigate the interactions of arbutin with calcium and oxalate
ions, two separate reaction mixtures containing 1 mM arbutin and 75 mM
calcium chloride solution and 1 mM arbutin: 75 mM sodium oxalate in
20 mM HEPES buffer (pH 7.4) were prepared. These reaction mixtures
were incubated at 37°C for 24 h and submitted for mass spectrometry at the
Mass Spectrometry Facility, University of Western Ontario, London, ON,
Canada. Samples were analyzed on a Bruker Daltonics Reflex IV research
grade MALDI time-of-flight (TOF) instrument equipped with a linear/
reflectron mass analyzer and postsource decay (PSD).
Crystallization of sodium oxalate in the presence and absence
of arbutin
To determine the effect of arbutin on the crystallization of calcium oxalate,
crystals of calcium oxalate were prepared by vapor diffusion, and 10 mM
sodium oxalate and calcium chloride solutions were prepared in ultrapure
water in separate glass vials of different sizes. The smaller glass vial
containing the calcium chloride solution was placed inside the larger vial
containing sodium oxalate. The system was loosely covered and allowed to
rest for a 3-week period with minimal disturbance. This experiment was
repeated in the presence of 1 mM arbutin. Crystals formed in the outer
oxalate-containing vial were collected to for further processing via confocal
microscopy and AFM.
Cytotoxicity assay of sodium oxalate and arbutin on human
kidney epithelial cells
HEK cells (HEK293; ATCC® CRL-1573™), were cultured in a six-well
plate containing 18-mm diameter glass coverslips to 50% confluence.
Following aspiration of culture medium, the cells were incubated in a
chloride-free solution containing 130 mM potassium gluconate, 5 mM
glucose, 20 mM HEPES (pH 7.4) and 20 μM sodium oxalate for 30 min.
The treated medium was then removed and stored at 4°C for further
analysis. Cells were washed with Cl−-free buffer and stained with 20 µM
CellTracker Red CMTPX Dye (Thermo Fisher Scientific) for 15 min.
Cells were triple washed with Cl−-free buffer and coverslips were mounted
with ProLong® Gold Antifade Mountant with DAPI (Thermo Fisher
Scientific), without permeabilizing, in preparation for confocal
microscopy. Samples were imaged using a Nikon A1R+ confocal
microscope (1.2 au) with a 20× dry or 60× oil immersion lens and
presented using NIS Elements software (Nikon).
The cytotoxicity of HEK293 cells in sodium oxalate medium with or
without arbutin was determined by quantifying lactose dehydrogenase
content liberated by damaged cells using a Cytotoxicity Detection KitPLUS
(LDH) (Roche), following the manufacturer’s instructions. Absorbance
readings were taken at 492 nm using a BioTek PowerWave HT Microplate
Spectrophotometer.
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